Aclarion (NASDAQ:ACON) Rating Increased to Hold at Wall Street Zen

Wall Street Zen upgraded shares of Aclarion (NASDAQ:ACON) to a hold rating in a report published on Saturday.

Separately, Weiss Ratings reiterated a “sell (e+)” rating on shares of Aclarion in a research note on Wednesday, October 8th. One research analyst has rated the stock with a Sell rating, Based on data from MarketBeat.com, the company has a consensus rating of “Sell”.

Aclarion Stock Down 8.3%

NASDAQ:ACON opened at $5.39 on Friday. Aclarion has a 52 week low of $5.02 and a 52 week high of $3,499.51. The company has a fifty day simple moving average of $6.68 and a two-hundred day simple moving average of $7.24. The company has a market cap of $3.61 million, a price-to-earnings ratio of -0.36 and a beta of 1.43.

Aclarion (NASDAQ:ACON) last released its earnings results on Wednesday, November 12th. The company reported ($2.93) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($2.64) by ($0.29). Aclarion had a negative net margin of 10,908.50% and a negative return on equity of 67.53%. The company had revenue of $0.02 million during the quarter, compared to analysts’ expectations of $0.02 million. On average, analysts expect that Aclarion will post -263.33 EPS for the current year.

About Aclarion

Aclarion, Inc, a healthcare technology company, leverages for Magnetic Resonance Spectroscopy (MRS) in the United States. It develops NOCISCAN Post-Processor suite of software applications comprising NOCICALC that receives the raw un-processed NOCISCAN MRS exam data and post-processes that raw data into final spectra and performs various degenerative pain biomarker; and NOCIGRAM, a clinical decision support software. The company was formerly known as Nocimed, Inc and changed its name to Aclarion, Inc in December 2021.